El Paso County Public Health

Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.

Clinical cases with magnetic foreign bodies of the gastrointestinal tract in children, diagnostic features, and the importance of timely endoscopic treatment are presented.

A lack of highly reliable, full state-space awareness of roadway situations is the current bottleneck for the incremental introduction of smart infrastructure control. NREL's Infrastructure Perception and Control (IPC) lab applies advanced sensing and computation controls to the coordinated movement of vehicles on the road as well as people in large facilities and has produced field test results from a Colorado Springs intersection. In this presentation, NREL discusses the state of smart infrastructure control and opportunities for partnership.

The determination of thyroid-stimulating hormone (TSH) is a reliable test in the diagnosis of thyroid dysfunction. When interpreting the results of quantitative studies, clinicians and laboratory specialists most often resort to assessing the compliance of the result with reference intervals (RI). At the same time, each laboratory must determine them for the analytes being measured itself, based on the characteristics of the examined contingent, the characteristics of the analytical systems used, achieving the necessary diagnostic effectiveness of the methodology, and its own practical and economic capabilities. A retrospective analysis of TSH results obtained from patients under the age of 19 years was performed for 54970 patients without hypothyroidism, thyrotoxicosis and pituitary disorders. For this work, reagent kits “Roche Cobas”, “Mindray” and “Beckman Coulter” (ICLA) were used. As a result, RI was established for the study of TSH for three sets of reagents with appropriate equipment and for four age groups: 1 day – 6 months, 6 months – 7 years, 7–14 years, 14–19 years. This makes it possible to use RI as a screening for possible developmental pathology in childhood and to determine the limits of clinical decisions.

Studies suggest that the components of brain-evoked potentials (EPs) may serve as biomarkers of the post-traumatic stress disorder (PTSD) caused by participation in combat operations; however, to date, research remains fragmented, with no studies that have attempted to combine different paradigms. In addition, the mismatch negativity component has not been studied in a Russian sample of veterans with PTSD. To identify objective neurophysiological markers of combat-related PTSD using the method of auditory-evoked potentials in active and passive listening paradigms. The study included a recording of auditory EPs in an oddball paradigm in three settings: 1) directed attention to auditory stimuli, 2) passive listening while viewing a neutral video sequence, and 3) viewing a video sequence associated with a traumatic event. Combatants diagnosed with PTSD (18 people) were compared with mentally healthy civilian volunteers (22 people). An increase in the latency period of the early components of auditory EP (N100 and P200), an increase in the amplitude of the P200 component to a deviant stimulus, and a decrease to a standard one in the active listening paradigm were established in the PTSD group. There were no significant differences in the parameters of the P300 component. The characteristics of mismatch negativity in the passive paradigm were revealed: an increase in the phenomenon amplitude, both when shown a video sequence associated with a traumatic event and when shown a neutral video sequence. A binary logistic regression model constructed using the selected parameters showed that the identified characteristics can potentially be considered as diagnostic markers of PTSD in combatants, as the classification accuracy stood at 87% (sensitivity - 81%, specificity - 91%). Potential neurophysiological markers of PTSD are the following: the amplitude and latency of early components of auditory EPs in the paradigm of directed attention to stimuli and the amplitude of mismatch negativity during passive attention.

Lupus nephritis (LN) occurs in 35–60% of patients with systemic lupus erythematosus (SLE), often in the early stages of the disease. LN is one of the most severe manifestations of SLE and, if not treated promptly and effectively, can lead to rapid and severe loss of kidney function. Despite modern pharmacotherapy, 5–20% of patients develop end-stage renal failure within 10 years of diagnosis of LN. The main principle of LN therapy is to prevent deterioration of renal function, but a consensus on outcome assessment criteria and clinically relevant short- and long-term goals for LN therapy has not yet been reached. There is increasing evidence of the importance of repeat kidney biopsies to assess the outcomes of the initial phase of therapy and to determine the long-term prognosis of renal failure. It is believed that the information obtained from repeat biopsies can help to make optimal treatment decisions and thus increase the likelihood of achieving a complete renal response in the short term and a more favorable renal prognosis in the long term.We describe a clinical case of a young patient with highly active SLE and morphologically confirmed class IV-S LN. Repeat biopsy and clinical and laboratory examination, had confirmed a clinical and laboratory remission of the disease on the background of the therapy. This made it possible to reduce the dose of methylpednisolone and cytostatic drugs (mycophenolate mofetil) and to discontinue therapy with biologic diseasemodifying antirheumatic drug (rituximab).

Relevance. COVID-19 vaccination reduces mortality and the course of severe diseases. However, there is an insufficiency of studies evaluating factors leading to infection among COVID-19 vaccinated individuals.Aim. Identification of epidemiological features that distinguish cases of the disease in vaccinated and unvaccinated cohorts.Materials and methods. The analysis of the incidence of COVID-19 in 1126 hospitalized patients in the period from 23.06.2021 to 01.05.2022 was carried out taking into account the presence or absence of vaccination against the SARS-CoV-2 virus.Results. It was found that the risk of COVID-19 getting sick in the unimmunized was 1.5 times higher than in the vaccinated (p < 0.05). The incidence of hospitalization, due to the severity of the condition (moderate, severe and extremely severe), in unvaccinated people with no history of comorbidities, is more than 3 times higher than in vaccinated people (p < 0.05) in the same group. The probability of death from COVID-19 among vaccinated people is 1.5 times lower than among unimmunized people (p < 0.05). The age characteristic of mortality in vaccinated people shifts to the «senile» age (76.93 ± 1.32), while among the unimmunized, the age of death is closer to the category of «elderly» (73.74 ± 1.39 years) (p ≤ 0.05). In the structure of mortality among the vaccinated, the main share was made up of patients with a history of 3 to 7 concomitant systemic diseases (66.7%), while among the unvaccinated, the main share (74.5%) were patients either without comorbidities or with a history of 1 to 2 concomitant diseases.Conclusion. The results of the epidemiological features of the COVID-2 epidemic process have shown that vaccination against the SARS-CoV-2 virus is vital for elderly and senile people with comorbid conditions.

Objective. Early-onset gastric cancer (EOGC) constitutes a serious medical and social problem. Early-onset gastric cancer accounts for approximately 6% of all malignant epithelial neoplasms.Material and Methods. We reviewed retrospective and prospective randomized trials using Medline and Elibrary databases.Results. The applied significance of the molecular genetic classifications consist in the formation of groups for evaluating prognosis of the disease using multifactorial analysis. This classification indicates that EOGC diagnosed at a locally advanced stage and primary dissemination is most often caused by GS (TCGA) and MSS/EMT(ACRG) subtypes and is characterized by mutations in CDH1, RhoA, CLDN18-ARHGAP genes. These changes are accompanied by the prevalence of diffuse histological type of gastric cancer according to the Lauren classification and ulcerated or infiltrative type according to the Borrmann classification (type III and IV) with the presence of high-grade adenocarcinoma with a signet ring cell component.Conclusion. Considering the aggressiveness of gastric cancer in young patients, who more frequently present with locally advanced and metastatic disease at the time of diagnosis, there is a need for increased cancer alertness among physicians of other specialties, early endoscopic controls to detect cancer at early stages and benefit from both surgical and multimodal treatment.

BackgroundEven though the incidence of Multisystem Inflammatory Syndrome in children (MIS-C) is decreasing cases are still reported across the world. Studying the consequences of MIS-C enhances our understanding of the disease’s prognosis. The objective of this study was to assess short- and medium-term clinical outcomes of MIS-C.MethodsProspective observational cohort study at Municipal Children’s Hospital Morozovskaya, Moscow, Russia. All children meeting the Royal College of Paediatrics and Child Health (RCPCH), Centers for Disease Control and Prevention (CDC), or the World Health Organization (WHO) MIS-C case definition admitted to the hospital between 17 May and 26 October 2020 were included in the study. All survivors were invited to attend a clinic at 2 and 6 weeks after hospital discharge.Results37 children median age 6 years (interquartile range [IQR] 3.3–9.4), 59.5% (22/37) boys were included in the study. 48.6% (18/37) of patients required ICU care. One child died. All children had increased levels of systemic inflammatory markers during the acute event. Echocardiographic investigations identified abnormal findings in 35.1% (13/37) of children. 5.6% (2/36) of children were presenting with any symptoms six weeks after discharge. By six weeks the inflammatory markers were within the reference norms in all children. The echocardiographic evaluation showed persistent coronary dilatation in one child.ConclusionsDespite the severity of their acute MIS-C, the majority of children in our cohort fully recovered with none having elevated laboratory markers of inflammation at 6 weeks, few (< 10%) reporting persistent symptoms at 6 weeks, and only one with persistent echocardiographic abnormalities.

Competent triage of patients with COVID-19 pneumonia is not only about efficient allocation of hospital resources, but also about making timely decisions that can ultimately save the patient's life. When healthcare facility is overloaded, computed tomography to assess the severity of COVID-19-associated pneumonia in each individual case is not always possible. Alternative solutions, however, are opted.The aim of the study was to develop Lung UltraSound (LUS) protocols with high diagnostic potential for assessing the severity of pneumonia caused by COVID-19, which can be reliably used instead of CT during triage in an emergency setting.Materials and methods. We conducted a retrospective analysis of data on 161 hospitalized patients with confirmed pneumonia caused by COVID-19, subjected to both CT and LUS within 24 hours after hospitalization. Three consecutive LUS protocols, including two LUS developed by the NMHC (National Medical Surgical Center) authors, were tested to choose the most reliable protocol for assessing the severity of lung damage in pneumonia caused by COVID-19 (based on correlation with chest CT results). We also checked the applicability of LUS for the prognosis of the disease.Results. Moderate (50% CT) and severe (50% CT) lung damage can be distinguished when using both - the 16-zone and 12-zone LUS NMHC scanning protocols. The AUC for the ROC curves was almost identical: 0.83 (95% CI: 0.75–0.90 and 0.81 (95% CI: 0.73–0.88) for the 16-zone and 12-zone LUS NMHC protocols, respectively. The 16-zone LUS NMHC had an optimal threshold of 20 scores with a sensitivity of 67% and a specificity of 82%, while the 12-zone LUS NMHC provided an optimal threshold of 15 scores with the same sensitivity but lower specificity — only 73%. Neither the 16-zone nor the 12-zone NMHC LUS protocols could predict the outcome.Conclusion. The newly developed 16- and 12-zone LUS NMHC scanning protocols for patients with pneumonia caused by COVID-19 proved to be easy to implement, demonstrating a strong correlation with CT results. The 16-zone LUS NMHC protocol is probably more relevant for triage of patients with more than 50% of pulmonary tissue involvement based on CT data. Both protocols can be useful in emergency settings and in medical institutions with limited or no access to CT.